Press release | bit.bio raises $103 million in first close of Series B financing

November 5, 2021 | Published by bit.bio

series B web imagewave(1200 x 799 px)

 

The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM

 

CAMBRIDGE, UK, 5 November 2021 - today bit.bio announces the first close of their Series B financing of $103 million. 

New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.

The funding will accelerate the clinical development of the company’s proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. 

It will also support the continued growth of the company’s ioCells product portfolio - where opti-oxTM is used to create human cell products that are unique because they offer consistency at scale and the cells are highly defined. Access to ioCells enables our partners and customers to conduct translational research and drug development with physiologically relevant human cell models. Using human cells to bridge the translation gap in drug development will improve chances of clinical success and the potential to unlock a new generation of medicines.

bit.bio has already launched two products for research and drug discovery - glutamatergic neurons and skeletal myocytes - with disease models and other cell types to follow. 

 
“I’m thrilled that bit.bio is supported by world class investors and strategic partners. The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere.”
Mark Kotter

bit.bio CEO and founder

Notes to Editors

About bit.bio

Accelerated biomedical research, new generations of cures, increased global sustainability. These are in reach when biology transitions to engineering.

At bit.bio, we work relentlessly to achieve this goal. We combine the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines. 

Key facts

bit.bio was founded in 2016 by Dr Mark Kotter from his labs at Cambridge University after his discovery of the opti-oxTM technology.  Co-founder Florian Schuster joined in 2018 as the company continued to grow and develop.

The company now has over 130 employees and is headquartered in Cambridge, UK and San Francisco, US.

In July 2019, the company announced the closure of a $41.5m Series A fundraise. 

The company recently expanded its board to include:

  • Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the board.  
  • Sir Greg Winter, Nobel-winning scientist, and known for his work on monoclonal antibodies, is the founder of multiple successful biotech companies.  
  • Alan S. Roemer, biotechnology entrepreneur who launched Pharmasset and Roivant Sciences, has raised over $1.75 billion in private and public capital and consummated five IPOs

Media Contact: April Six on behalf of bit.bio

bitbio@aprilsix.com 

+44 7875 468942

Latest news